Causes arteriolar narrowing and high blood pressure (BP) with a possible reflex bradycardia. Compared with norepinephrine and epinephrine increased blood pressure less deca durabolin results sharply, but longer-acting (little exposed to the catechol-O-methyltransferase), does not cause an increase in cardiac output. The action starts immediately after injection and lasts for 20 min (after intravenous injection), 50 min (after subcutaneous injection), 2.1 hours (after intramuscular injection).
Metabolized in the liver and gastrointestinal tract (without catechol-O-methyltransferase). Excreted by the kidneys as metabolites.
collapse, hypotension (associated with a reduction in vascular tone), in preparation for the surgery and during operations, vasomotor rhinitis and hay, intoxications, as a vasoconstrictor with local anesthesia
Hypersensitivity to the drug, hypertrophic obstructive cardiomyopathy (including asymmetric hypertrophy of the septum), pheochromocytoma, tachyarrhythmia, atrial fibrillation and / or ventricular, metabolic acidosis, hypercapnia, hypoxia, hypertension, hypertension in the pulmonary circulation, hypovolemia, severe aortic stenosis, acute myocardial infarction, porphyria. congenital deficiency of glucose-6-phosphate dehydrogenase, the propensity to vascular spasm, pregnancy, lactation, age 18 years (effectiveness and safety have been established).
Precautions: Prinzmetal angina, occlusive vascular disease history, including arterial thrombosis, atherosclerosis, thromboangiitis obliterans (Buerger’s disease), frostbite, diabetic endarteritis, Raynaud’s disease, hyperthyroidism, advanced age, diabetes mellitus, when general anesthesia (ftorotanovy) renal impairment.
Dosing and Administration
Mezaton administered intravenously, subcutaneously, intramuscularly, intranasally. When the drug is administered collapse usually intravenously in doses 0,1-0,3-0,5 ml of a 1% solution, diluted with 20 ml of 5% – 20% solution of dextrose (glucose) or 0.9% sodium chloride solution. Administration is slow, administration is repeated when necessary. In drip administered 1 mL of 1% phenylephrine solution in 250-500 ml of 5% dextrose (glucose). Intramuscularly and subcutaneously administered to adults in doses of 0.3-1 ml of a 1% solution.
With a view to narrowing of blood vessels of the mucous membranes of the nasal cavity and reduce the severity of inflammation buried 0.25-0.5% solutions or mucous membrane smeared with these solutions. The local anesthetic (10 ml anesthetic) was added 0.3-0.5 ml of a 1% solution of phenylephrine.
Higher doses for adults: IV – single 0,005 grams daily – 0,025 g; subcutaneously and intramuscularly – single 0.01 g daily – 0.05 g
Side effect On the part of the cardiovascular system: increased blood pressure, heart rate, cardiac ventricular deca durabolin results fibrillation, arrhythmia, bradycardia, cardialgia.
From the gastrointestinal tract: dyspepsia;
On the part of the central nervous system: dizziness, anxiety, insomnia, anxiety, weakness, headache, tremor, paresthesia, seizures, brain hemorrhage;
Other: pale skin, ischemia of the skin at the injection site, in rare cases, possible necrosis and scab formation in contact with the tissues or subcutaneous injection, and allergic reactions.
symptoms: ventricular premature beats, short paroxysms of ventricular tachycardia, a feeling of heaviness in the head and limbs, a significant increase in blood pressure.
Treatment: intravenous alpha-adrenergic blockers (phentolamine) and beta-blockers (for heart rhythm disturbances).
Interaction with other drugs
Phenothiazines, alpha-blockers (phentolamine), furosemide and other diuretics reduce the hypertensive effect.
Monoamine oxidase inhibitors, oxytocin, ergot alkaloids, tricyclic antidepressants, furazolidin, procarbazine, selegiline, adrenostimulyatorov increase pressor effect, and the latter – and arrhythmogenic.
Beta-blockers decrease the cardio activity on the background of reserpine possible hypertension (due to depletion of catecholamines stocks adrenergic endings increases sensitivity to adrenoceptor agonists).
During treatment should monitor the ECG, blood pressure, cardiac output, blood circulation in the limbs and at the injection site.
Before the start or during treatment required correction of hypovolemia, hypoxia, acidosis, hypercapnia.
The sharp increase in blood pressure, bradycardia or tachycardia, persistent cardiac arrhythmias require discontinuation of treatment. To prevent re-BP reduction after the drug dose should be reduced gradually, especially after prolonged infusion. Infusion renew if systolic blood pressure is reduced to 70-80 mm Hg. Art.
During treatment should not engage in dangerous activities that require speed motor and mental deca durabolin results reactions (including driving)